Skip to content
Search

Latest Stories

HayMax wins Leading Pharmaceutical Company title at M&A Today Global Awards

The global award recognises HayMax innovative product and expansion into overseas markets 

HayMax, maker of the organic drug-free allergen barrier balm, has been honoured in the M&A Today Global Awards 2024, winning in the category of Leading Pharmaceutical Company.

These awards celebrate ‘unparalleled excellence globally’, with participation from over 163 countries.


HayMax stated that its achievement in the M&A Today Awards underscores the company's "dedication and strategic innovation in the industry," distinguishing it as a global leader.

Max Wiseberg, Managing Director of HayMax, expressed his delight stating “This is a great achievement for a small company to win on a global scale.”

He said that this global award is a recognition of their “innovative product and expansion into overseas markets” from their traditional UK base.”

The company noted that its focus on prevention sets itself apart from most other hay fever treatments and remedies.

The balm aims to stop pollen from entering the body before it can cause a reaction, rather than treating symptoms after they occur. This simple yet effective approach has earned HayMax a loyal following.

Over nearly two decades, the company has won more than 60 awards, including the 2023 Soil Association BOOM Award, British Made Award, Enterprise Award, BizzieBaby Award, Global 100 Award, and Corporate America Today Annual Award.

The M&A Today Global Awards are known for their thorough and objective selection process, which ensures that only truly exceptional firms are recognized.

The selection process is rigorous, with the assessment stage involving a combination of self-submission and third-party nominations.

Organisers conduct an in-depth analysis of the company's domestic and international activities, focusing on strategic depth and complexity to form a list of elite firms.

An expert panel of independent judges then reviews this list, evaluating the strategic nature and complexity of projects, operational scale, speed, budget efficiency, and innovative approaches.

More For You

Pharmacist handing medicine to patient, NHS prescription cost freeze debate

Prescription charge will remain at £9.90

Pic credit: iStock

NPA calls for end to prescription charge after freeze announcement

The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.

Patients will continue paying £9.90 to collect their medication from a pharmacy.

Keep ReadingShow less
RPS launches new prescribing development programme for pharmacists

From 2026, every newly qualified pharmacist will be an independent prescriber

gettyimages

RPS unveils new training programme to enhance pharmacists’ prescribing skills

The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.

Keep ReadingShow less
Varenicline promotes nicotine vaping cessation in young people

Researchers warn that e-cigarette use can increase risk for nicotine addiction,uptake of combusted tobacco and other substance use.

gettyimages

Anti-smoking pill varenicline may help young people quit vaping, new study suggests

Varenicline — a daily pill already offered through NHS Stop Smoking Services — could also support young people in quitting vaping, new research has suggested.

The medication, proven to be more effective than nicotine replacement gums or patches for smoking cessation, was shown to significantly boost vaping abstinence when combined with behavioural counselling in adolescents and young adults.

Keep ReadingShow less
Relying on blue inhalers alone can worsen asthma symptoms, warns MHRA

Patients are advised to use their preventer inhaler regularly, even if their asthma feels under control.

Pic credit: gettyimages

Overuse of blue inhalers can increase risk of severe asthma attacks, warns MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding asthma patients to use their preventer (anti-inflammatory) inhalers regularly as prescribed, rather than relying solely on their blue inhalers, also referred to as reliever inhalers.

“Without regular use of a preventer inhaler, symptoms could worsen and increase the risk of severe asthma attacks,” the MHRA warned.

Keep ReadingShow less
13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less